The MarketWatch News Department was not involved in the creation of this content. Glucagon-Like Peptide-1 Analogues Market to Surpass USD 299.08 Billion by 2033, Fueled by the Weight Management and ...

A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...

Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...

"The market for GLP-1 agonists is highly consolidated, with key players strategizing to capture the market. Prominent players ...

The deal focuses on a weight-loss pill in development at YaoPharma, a GLP-1 agonist codenamed YP05002, which is currently in ...

Weight loss jabs could help reduce alcohol consumption in obese people by around two thirds, a new study suggests. Researchers believe the drugs, known as GLP-1 receptor agonists, could curb alcohol ...

The UC Davis Innovation Institute for Food and Health recently hosted scientists, physicians and industry experts to discuss how drugs based on GLP-1 are transforming treatment for obesity, diabetes ...

New trial finds liraglutide reduces brain shrinkage by nearly 50% in Alzheimer’s patients and slows cognitive decline by up to 18% ...

GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...

As the global pet obesity rate reaches alarming levels, Okava Pharmaceuticals, a San Francisco-based firm, launched a GLP-1-based pet weight management pilot study, MEOW-1 (Management of Overweight ...

† Deaths in LEAD-2: one in the run-in period, one after trial correction for hepatocellular carcinoma; deaths in LEAD-3: car accident. ‡ Only one out of five major hypoglycemic episodes required ...